Guide · Services / Agentic AI in Pharma
Agentic AI in Pharma — governance first.
A practical guide for medical, commercial and IT leaders on running multi-agent systems inside large pharma — across CRM, regulatory, medical and commercial stacks — without losing the audit trail, compliance posture or human accountability the industry demands.
Why now
From copilots to coordinated agent fleets
The first wave of generative AI in pharma was single-prompt copilots glued onto Word, email and chat. They were useful, but bounded — one user, one document, one turn. The second wave is agentic: systems that plan a goal, decompose it, call tools, work across systems, and report back with citations and a full audit trail.
The shift matters because most pharma work is multi-system by nature. A medical information request touches CRM, the medical content library, PV intake and the approval queue. Coordinating that with a single prompt isn't realistic — coordinating it with a small team of scoped agents is.
Orchestration
One coordinator, many specialists
The architecture we deploy in pharma follows the same shape across clients: a coordinator agent that owns the goal, specialist agents with scoped permissions and tools, and a guardrail layer enforcing policy on every input and output.
┌────────────────────────────┐
│ Coordinator Agent │
│ (planning + delegation) │
└─────────────┬──────────────┘
│
┌──────────────────────┼──────────────────────┐
▼ ▼ ▼
┌────────┐ ┌──────────┐ ┌────────────┐
│ CRM │ │ Medical │ │ Regulatory │
│ Agent │ │ Agent │ │ Agent │
│(Veeva, │ │(MedComms,│ │(RIM, eCTD, │
│ SFDC) │ │ MLR) │ │ Labels) │
└───┬────┘ └────┬─────┘ └─────┬──────┘
│ │ │
└──────── Guardrails · Audit log · HITL ────┘Each specialist agent inherits row-level permissions from its source system. An MSL agent acting for a user can only see what that user is entitled to see in Veeva. A regulatory agent cannot publish anything without an explicit human approval. The coordinator never bypasses these constraints — it routes around them.
Governance & compliance
What large pharma actually requires
- Audit trail by default. Every tool call, prompt, retrieved document and model response is logged with user, timestamp and version — queryable for inspection.
- GxP risk classification. Each agent is scoped, validated and version-controlled following GAMP 5 categories; changes go through change control.
- Pharmacovigilance signal handling. Any agent that touches HCP or patient conversations has a PV detector that escalates suspected adverse events into the existing intake pipeline within 24 hours.
- Human-in-the-loop on external content. Anything bound for HCPs, patients or regulators routes through MLR before it ships — no exceptions.
- Data residency and privacy. EU and US residency by default, GDPR / HIPAA aligned, BYO-key supported, private model deployments where the use case requires it.
- Model risk management. Per-agent evaluation suites, drift monitoring, and a documented fallback when a model fails or degrades.
Use cases
Where agentic AI is already paying back
- MLR pre-review. An agent flags off-label, missing citations and PI inconsistencies before a piece ever reaches the human reviewer — cycle time drops 40–70%.
- Advisory board synthesis. Built into ADVISA: agents transcribe, tag and synthesise KOL input across sessions, surfacing evidence-linked themes for medical strategy.
- Congress intelligence. Wired into NEO Pro: agents monitor a congress in real time, summarise sessions, and brief field teams before the next morning.
- Emotion-aware engagement. Combined with AuraINSIGHTS, agents adapt content and follow-ups based on observed engagement signals — with consent and audit.
- Crisis-comms triage. Embedded in Crisis Protecta: agents draft role-specific response templates, route them through approvals, and track resolution.
FAQ
Common questions from medical, commercial and IT leaders
What is agentic AI in pharma?
Agentic AI in pharma refers to multi-agent systems that plan, call tools, and execute work across CRM, regulatory, medical and commercial stacks — not single-prompt copilots. A coordinator agent decomposes a goal (e.g. respond to a medical information request) and delegates to specialist agents with scoped permissions, evidence sources and guardrails.
How do you validate agentic systems for GxP and MLR contexts?
We treat agents like any other GxP-relevant software: documented intended use, risk classification (GAMP 5), traceable requirements, deterministic eval suites per agent, and human-in-the-loop sign-off for any output that touches HCPs, patients or regulators. Every tool call and model response is logged for audit.
Can agentic AI work with Veeva, Salesforce, RIM and our medical content stack?
Yes. Agents integrate via existing APIs and SSO. We typically wire Veeva CRM / Vault, Salesforce Health Cloud, RIM / eCTD systems, MedComms libraries and PV intake — with row-level permissions inherited from the source system so an agent can never see more than the user it acts for.
How do you prevent hallucinations and off-label content?
Three layers: retrieval grounded in approved evidence, output classifiers that block off-label or unapproved claims, and a mandatory MLR human-in-the-loop step for any externally bound content. Every claim is traced back to a source document with a citation.
How is data privacy handled — GDPR, HIPAA, patient data?
Patient and HCP data stays in-region, encrypted at rest and in transit, with DPAs and DPIAs in place. We default to EU and US data residency, support BYO-key, and run private model deployments (Azure OpenAI, AWS Bedrock, on-prem LLMs) when the use case requires it.
What's the typical ROI and time-to-value?
First production agents typically ship in 8–12 weeks against a single high-value workflow — MLR pre-review, medical information triage, congress intelligence or advisory board synthesis. ROI shows up as cycle-time reduction (often 40–70%) and reclaimed medical and commercial capacity.
Plan your first production agent with us.
A two-hour working session with our medical, engineering and governance leads. You leave with a scoped use case, a validation plan and a realistic time-to-value.